Extended indication Treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows.
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Botulinum A toxin
Domain Neurological disorders
Reason of inclusion New medicine (specialité)
Main indication Muscular diseases
Extended indication Treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows.
Manufacturer Evolus
Route of administration Intramuscular
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity New therapeutical formulation
Submission date August 2017
Expected Registration February 2019
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.